Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1456343

Case Report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response

Provisionally accepted
Qinghua QingHua Liu Qinghua QingHua Liu 1Ruoyun Li Ruoyun Li 1*Wei Zhu Wei Zhu 2*Pengfei Zheng Pengfei Zheng 3*
  • 1 Lanzhou University Second Hospital, Lanzhou, China
  • 2 Department of Pathology,, Lanzhou University Second Hospital, Lanzhou, China
  • 3 Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China

The final, formatted version of the article will be published soon.

    Pancreatic adenosquamous carcinoma (PASC) is a rare subtype of pancreatic cancer (PC), with no established consensus on the optimal treatment for postoperative liver metastasis recurrence. We report a case of a 48-year-old male patient who underwent radical surgery and was pathologically diagnosed with microsatellite instability-high (MSI-H) PASC. The patient experienced liver metastasis recurrence following single-agent gemcitabine adjuvant chemotherapy. After one session of transarterial chemoembolization (TACE) with oxaliplatin, fluorouracil, and epirubicin, followed by six cycles of adjuvant chemotherapy with gemcitabine and nab-paclitaxel combined with sintilimab immunotherapy and bevacizumab targeted therapy, complete pathological regression of the liver metastasis was achieved. The patient has now reached a 24-month survival period and continues to be monitored at our center. This case illustrates the promise of the proposed treatment regimen, highlighting the significant potential of multimodal multimodality strategies in managing metastatic recurrence of MSI-H PASC.

    Keywords: Pancreatic adenosquamous carcinoma, Microsatellite instability-high, Chemotherapy Immunotherapy, targeted therapy, Recurrence, metastasis

    Received: 28 Jun 2024; Accepted: 26 Nov 2024.

    Copyright: © 2024 Liu, Li, Zhu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ruoyun Li, Lanzhou University Second Hospital, Lanzhou, China
    Wei Zhu, Department of Pathology,, Lanzhou University Second Hospital, Lanzhou, China
    Pengfei Zheng, Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.